Aratana Therapeutics (PETX) Reports In-Line Q1 EPS

Aratana Therapeutics (NASDAQ: PETX) reported Q1 EPS of ($0.34), in-line with the analyst estimate of ($0.34). Revenue for the quarter came in at $3.8 million versus the consensus estimate of $3.07 million.

For earnings history and earnings-related data on Aratana Therapeutics (PETX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Movano (MOVE) Misses Q2 EPS by 195c
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c